Moxifloxacin monotherapy equivalent to antibiotic combo

Moxifloxacin monotherapy equivalent to antibiotic combo
Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer and neutropenia who are at low risk of complications, according to a study published online Jan. 28 in the Journal of Clinical Oncology.

(HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer and neutropenia who are at low risk of complications, according to a study published online Jan. 28 in the Journal of Clinical Oncology.

Winfried V. Kern, M.D., from the University Hospital in Freiburg, Germany, and colleagues conducted a double-blind multicenter study to compare the efficacy and safety of with oral combination therapy for febrile neutropenia in cancer patients with low risk of complications as defined by a Multinational Association for Supportive Care in Cancer score >20. Patients were assigned to receive either moxifloxacin monotherapy or oral ciprofloxacin plus amoxicillin/clavulanic acid.

The researchers found that, among the 333 patients included in the intention-to-treat analysis, therapy success was seen in 80 percent of the patients administered moxifloxacin and 82 percent of the patients administered combination therapy (95 percent confidence interval for the difference, −10 to 8 percent, consistent with equivalence). There were minor differences in tolerability, safety, and reasons for failure, but in the two groups, more than 50 percent of patients were discharged on protocol therapy, with 5 percent readmissions in each group. Survival was 99 percent in both groups.

"In conclusion, the data from this double-blind trial provide evidence that single-drug oral therapy in low-risk febrile neutropenia with moxifloxacin is equivalent to the so far considered standard," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bayer Healthcare, which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Sequential oral, topical tacrolimus benefits dermatitis

Sep 20, 2012

(HealthDay)—Sequential therapy with oral tacrolimus and topical tacrolimus may be an effective treatment for severe atopic dermatitis (AD), according to a pilot study published in the October issue of the ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.